CDCA7L

Across TCGA pan-cancer cohorts, CDCA7L mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated CDCA7L data layer compared with 28 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher CDCA7L mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated CDCA7L expression acts as an unfavorable survival marker, although some lineages such as LSCC show a favorable association.

UCEC, LUAD, and LSCC are the cancer types where CDCA7L mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UCEC	DFS	Quartile	II,III,IV	0.398	1.000	.040	4	view →
LUAD	DFS	Median	All	0.891	1.000	.031	3	view →
LSCC	OS	Tertile	II,III,IV	0.901	0.629	.045	2	view →
HNSC	OS	Tertile	All	0.770	0.910	.047	1	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

CDCA7L–UCEC (DFS)

Open the UCEC breakdown →